NCI-H358細(xì)胞

生長(zhǎng)狀態(tài)： 貼壁生長(zhǎng)

組織來(lái)源： bronchiole; alveolus

ATCC Number： CRL-5807?

相關(guān)**： 其他**

細(xì)胞形態(tài)： 上皮樣

運(yùn)輸方式： 凍存運(yùn)輸

是否是腫瘤細(xì)胞： 1

物種來(lái)源： 人

器官來(lái)源： 肺

數(shù)量： 大量

Designations: NCI-H358 [H-358, H358]

Depositors: AF Gazdar, JD Minna

NCI-H358細(xì)胞Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: lung

Tissue: bronchiole; alveolus

Disease: bronchioalveolar carcinoma; non-small cell lung cancer

Cellular Products: lung surfactant associated protein A (SP-A)

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. NCI-H358細(xì)胞They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

Isolation: Isolation date: 1981

Tumorigenic: Yes

DNA Profile (STR): Amelogenin: X,Y

CSF1PO: 11,12

D13S317: 8,12

D16S539: 12,13

D5S818: 10,12

D7S820: 10,11

THO1: 6

TPOX: 8,9

vWA: 17

GenoType: EGFR (wt) [90471]

Gender: male

Comments: NCI-H358細(xì)胞This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates in 1981 from tumor tissue obtained from a patient prior to initiation of chemotherapy.

Ultrastructural studies demonstrated the presence of cytoplasmic structures characteristic of Clara cells.

The cells expressed protein and RNA of SP-A, the major lung surfactant associated protein.

SP-B and SP-C RNA was not expressed.

They have a reported colony forming efficiency of 0.83% in soft agarose.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Protocol: Remove medium, and rinse with 0.25% trypsin, 0.53 mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.

Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended

Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%

Storage temperature: liquid nitrogen vapor temperature

Doubling Time: 38 hrs

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

purified DNA:ATCC CRL-5807D

References: 22434: Brower M, et al. NCI-H358細(xì)胞Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46: 798-806, 1986. PubMed: 3940644

23081: Gazdar AF, et al. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 50: 5481-5487, 1990. PubMed: 2386953

23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..

90471: Sordella R, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004. PubMed: 15284455